Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.62) per share which missed the analyst consensus estimate of $(1.23) by 31.71 percent. This is a 8 percent decrease over losses of $(1.50) per share from the same period last year.
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.62) per share which missed the analyst consensus estimate of $(1.23) by 31.71 percent. This is a 8 percent decrease over losses of $(1.50) per share from the same period last year.
Comments